Join
Live feed
·
PRReleasevia Quantisnow
Passage Bio Inc. logo

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

ByQuantisnow·Wall Street's wire, on your screen.
PASG· Passage Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PASG (Passage Bio Inc.) and more on Quantisnow.